Search Results - "Hamadi, Zouabi"

Ofatumumab in poor-prognosis chronic lymphocytic leukemia: a phase IV, non-interventional, observational study from the European Research Initiative on Chronic Lymphocytic Leukemia by Moreno, Carol, Montillo, Marco, Panayiotidis, Panayiotis, Dimou, Maria, Bloor, Adrian, Dupuis, Jehan, Schuh, Anna, Norin, Stefan, Geisler, Christian, Hillmen, Peter, Doubek, Michael, Trněný, Marek, Obrtlikova, Petra, Laurenti, Luca, Stilgenbauer, Stephan, Smolej, Lukas, Ghia, Paolo, Cymbalista, Florence, Jaeger, Ulrich, Stamatopoulos, Kostas, Stavroyianni, Niki, Carrington, Patrick, Zouabi, Hamadi, Leblond, Veronique, Gomez-Garcia, Juan C, Rubio, Martin, Marasca, Roberto, Musuraca, Gerardo, Rigacci, Luigi, Farina, Lucia, Paolini, Rossella, Pospisilova, Sarka, Kimby, Eva, Bradley, Colm, Montserrat, Emili

“…We report the largest retrospective, phase IV non-interventional, observational study of ofatumumab therapy in heavily pre-treated patients with poor-prognosis…”
Get full text

A Multicenter, Phase IV Observational Study Of Ofatumumab In Chronic Lymphocytic Leukemia (CLL): A European Research Initiative On CLL (ERIC) Study by Moreno, Carol, Montillo, Marco, Panayiotis, Panayiotidis, Bloor, Adrian, Dupuis, Jehan, Schuh, Anna, Norin, Stefan, Geisler, Christian H, Hillmen, Peter, Doubek, Michael, Obrtlikova, Petra, Laurenti, Luca, Stilgenbauer, Stephan, Smolej, Lukas, Ghia, Paolo, Cymbalista, Florence, Jaeger, Ulrich, Stavroyianni, Niki, Carrington, Patrick, Zouabi, Hamadi, Leblond, Veronique, Gomez, Juan Carlos, Marasca, Roberto, Musuraca, Gerardo, Rigacci, Luigi, Farina, Lucia, Paolini, Rossella, Pospisilova, Sarka, Kimby, Eva, Bradley, Colm, Montserrat, Emili

“…Ofatumumab was given a conditional approval in the EU on April 2010 for the treatment of CLL refractory to fludarabine (F-ref) and alemtuzumab (A-ref),…”
Get full text

Intravenous Busulfan-Based Conditioning Prior to Allogeneic Stem Cell Transplantation in Adults Patients with AML - An ALWP-EBMT Survey by Nagler, Arnon, Labopin, Myriam, Shimoni, Avichai, Bunjes, Donald, Pimentel, Pedro, Socie, Gerard, Boudjedir, Karim, Zander, Axel R., Gomez, A. Torres, Baccarini, Michele, Goker, Hakan, Fassas, Athanasios, Kenzey, Chantal, Samey, Benedicte, Hamadi, Zouabi, Rocha, Vanderson

“…Oral Busulfan (Bu) is the historical backbone of pre-allogeneic stem cell transplantation (alloSCT) conditioning regimen. However, oral Bu has an erratic and…”
Get full text

I.V. Busulfan Given Based on Body Weight in Combination with Cyclophosphamide in Children: Pharmacokinetic and Clinical Results of a Myeloablative, Reduced-Toxicity Conditioning Regimen for Allogeneic Stem Cell Transplantation by Esperou, Helene, Neven, Bénédicte, Yakouben, Karima, Galambrun, Claire, Méchinaud, Françoise, Paillard, Catherine, Bordigoni, Pierre, Zouabi, Hamadi, Nguyen, Laurent, Michel, Gérard, Vassal, Gilles

“…Background: In children busulfan (Bu) is often included in conditioning regimens prior to allogeneic (allo-) haematopoietic stem cell transplantation (HSCT)…”
Get full text

A New IV Busulfan Fixed Dosing as Part of BuMel or BuCy Conditioning Regimens: A Pharmacokinetic/Pharmacodynamic Study in Pediatric Patients Undergoing Autologous or Allogeneic Hematopoietic Stem Cell Transplantation by Vassal, Gilles, Esperou, Hélène, Valteau-Couanet, Dominique, Gentet, Jean Claude, Doz, François, Méchinaud, Françoise, Galambrun, Claire, Fischer, Alain, Zouabi, Hamadi, Nguyen, Laurent, Michel, Gérard

“…Background: Busulfan (Bu) given in myeloablative doses is frequently included in hematopoietic stem cell transplantation (HSCT) regimens for pediatric (Ped)…”
Get full text

A New Busulfan Fixed Dosing for Conditioning before Autologous or Allogeneic Hematopoietic Stem Cell Transplantation in Children with Malignant and Non-Malignant Diseases: Pharmacokinetics, Toxicity and Clinical Outcomes by Michel, Gérard, Valteau-Couanet, Dominique, Esperou, Hélène, Gentet, Jean Claude, Doz, François, Méchinaud, Françoise, Galambrun, Claire, Fischer, Alain, Zouabi, Hamadi, Puozzo, Christian, Vassal, Gilles

“…Background: Oral busulfan (Bu) is a standard component of hematopoietic stem cell transplantation (HSCT) regimens in pediatric patients (pts). Bu exposure…”
Get full text

Intensive Chemotherapy with Hematopoietic Cell Transplantation after ESHAP Therapy for Relapsed or Refractory Non-Hodgkin's Lymphoma. Results of a Single-Centre Study of 65 Patients by Soussain, Carole, Souleau, Bertrand, Gabarre, Jean, Zouabi, Hamadi, Sutton, Laurent, Boccaccio, Catherine, Albin, Nicolas, Charlotte, FrÉDÉRic, Merle-béral, HÉLÉNe, Delort, JosÉE, Binet, Jacques-Louis, Leblond, VÉRonique

“…This study was designed to assess the results of protracted courses of ESHAP (etoposide, cyt-arabine, cisplatin, methylprednisolone) therapy followed by…”
Get full text

Late CD8+ lymphocytic alveolitis after allogeneic bone marrow transplantation and chronic graft-versus-host disease by Leblond, V, Zouabi, H, Sutton, L, Guillon, J M, Mayaud, C M, Similowski, T, Beigelman, C, Autran, B

“…Late-onset interstitial pneumonitis following allogeneic bone marrow transplantation (BMT) is a rare condition usually caused by a variety of infective agents,…”
Get more information